Relation of CD94/NKG2C expression and HCMV serology
Receptor* . | Subset* . | HCMV-negative†§ . | HCMV-positive†§ . | P‡ . |
|---|---|---|---|---|
| NKG2A | Total | 11.1 ± 4.5 (4.3-23) | 9.5 ± 4.2 (1.3-18) | .2 |
| CD3+ | 4.7 ± 3.4 (1.2-18) | 4.6 ± 3 (1-14) | .8 | |
| CD3- | 25.6 ± 8.7 (10-44) | 25.1 ± 11.3 (1.6-56) | .8 | |
| CD3-CD56+∥ | 45.4 ± 12.5 (23.5-62.7) | 37.8 ± 21 (12.3-75) | .4 | |
| NKG2C | Total | 0.33 ± 0.4 (0.1-1.7) | 3.5 ± 4.4 (0.1-22.1) | < .001 |
| CD3+ | 0.3 ± 0.5 (0.1-1.9) | 0.9 ± 1 (0.1-5) | < .001 | |
| CD3- | 0.9 ± 1 (0.1-5.9) | 8.2 ± 10.4 (0.1-45) | < .001 | |
| CD3-CD56+∥ | 1.7 ± 1.6 (0.1-6) | 25.3 ± 25.1 (2.5-80) | < .001 | |
| NKG2A/NKG2C ratio | Total | 60.7 ± 44.5 (6.4-163) | 16.1 ± 29.4 (0.29-161) | < .001 |
Receptor* . | Subset* . | HCMV-negative†§ . | HCMV-positive†§ . | P‡ . |
|---|---|---|---|---|
| NKG2A | Total | 11.1 ± 4.5 (4.3-23) | 9.5 ± 4.2 (1.3-18) | .2 |
| CD3+ | 4.7 ± 3.4 (1.2-18) | 4.6 ± 3 (1-14) | .8 | |
| CD3- | 25.6 ± 8.7 (10-44) | 25.1 ± 11.3 (1.6-56) | .8 | |
| CD3-CD56+∥ | 45.4 ± 12.5 (23.5-62.7) | 37.8 ± 21 (12.3-75) | .4 | |
| NKG2C | Total | 0.33 ± 0.4 (0.1-1.7) | 3.5 ± 4.4 (0.1-22.1) | < .001 |
| CD3+ | 0.3 ± 0.5 (0.1-1.9) | 0.9 ± 1 (0.1-5) | < .001 | |
| CD3- | 0.9 ± 1 (0.1-5.9) | 8.2 ± 10.4 (0.1-45) | < .001 | |
| CD3-CD56+∥ | 1.7 ± 1.6 (0.1-6) | 25.3 ± 25.1 (2.5-80) | < .001 | |
| NKG2A/NKG2C ratio | Total | 60.7 ± 44.5 (6.4-163) | 16.1 ± 29.4 (0.29-161) | < .001 |
NKG2A+ (Z199+) and NKG2C+ (p25+Z199- or MAB1381-) cell subsets were defined by flow cytometry
Blood donors were classified according to the detection of serum HCMV-specific IgG in HCMV-positive (n = 34) and HCMV-positive (n = 34). The number of samples in which CD3-CD56+ cells were analyzed is specified in the footnote below (∥)
Statistical analysis according to the Mann-Whitney U test
Data are expressed as mean ± SD (range)
In CD3-CD56+ cells the expression of NKG2A (n = 11 HCMV-negative; n = 8 HCMV-positive) and NKG2C (n = 11 HCMV-negative; n = 10 HCMV-positive) was defined by 3-color analysis